ALK L1196M mutación de resistencia del portero
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | BIO-ALK-L1196M |
|---|---|
| Tipo | Biomarcador |
| Aliaces | ALK L1196M mutación de porteroALK L1196M — мутація резистентності (gatekeeper)ALK gatekeeperALK p.L1196M |
| Situación | reviewed 2026-04-27 | pending_clinical_signoff |
| Enfermedades | DIS-IMT |
| Fuentes | SRC-ALEX-PETERS-2017 SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Datos sobre biomarcadores
| Tipo de biomarcador | gene_mutation |
|---|---|
| Detalles de la mutación | {"exón": "23", "functional_impact":"resistencia del portero al crizotinib (1st-gen) y resistencia parcial al alectinib; sensible a brigatinib, ceritinib y lorlatinib", "geno": «ALK», «hgvs_protein»: «p.L1196M», «variant_type»: "misense"} |
| Medición | MétodoctDNA NGS a la progresión; tumor re-biopsia NG Unidadescategorical (positive | negative); VAF % when reported |
| Consulta de la capacidad de acción | {"gene": "ALK", "variante":"L1196M"} |
| Productos químicos y químicos | BIO-ALK-FUSION BIO-ALK-REARRANGEMENT BIO-ALK-G1202R |
Notas
Classical ALK gatekeeper mutation (analogous to EGFR T790M, BCR::ABL1 T315I). Most frequently seen as acquired resistance after crizotinib (1st-gen). 2nd-generation TKIs (alectinib, brigatinib, ceritinib) retain activity — alectinib superiority over crizotinib in 1L (ALEX, Peters 2017) is partly explained by avoidance of L1196M-mediated resistance. Lorlatinib also active. Compound mutations involving L1196M (e.g., L1196M + G1202R) emerge under sequential TKI pressure and require trial-based strategies.
Utilizado por
Biomarcador
BIO-ALK-G1202R- Mutación de resistencia ALK G1202R
Señal de alerta
RF-IMT-TRANSFORMATION-PROGRESSION- IMT progression on first-line crizotinib (acquired ALK kinase-domain resistance mutation...